More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$37.07B
EPS
2.32
P/E ratio
40
Price to sales
3.33
Dividend yield
--
Beta
0.104162
Previous close
$251.65
Today's open
$248.97
Day's range
$248.27 - $252.72
52 week range
$160.36 - $261
show more
CEO
Christopher A. Viehbacher
Employees
7500
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
147820223
Issue type
Common Stock
Healthcare
Pharmaceuticals
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, and additional sex-based outcomes TOKYO and CAMBRIDGE, Mass., Nov. 18, 2026 /PRNewswire/ -- Eisai Co., Ltd.
PRNewsWire • 16 minutes ago

Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Reuters • 18 hours ago

Biogen: 3 Key Takeaways for Long-Term Investors
Total third quarter core pharmaceutical revenue reached $2 billion. Growth portfolio revenue rose 49% year over year in Q3.
The Motley Fool • 19 hours ago

Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen NASDAQ: BIIB expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference.
MarketBeat • 17 hours ago

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of publicly-traded Biogen Inc. common stock– BIIB
BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly-traded Biogen Inc. common stock (NASDAQ: BIIB): UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ALBERT AFTOORA and AMJAD KHAN Individually and On Behalf of All Others Similarly Situated, and NADIA SHASH as Sole Managing Member of PolyCon Solutions LLC, individually, Plaintiffs, v.
GlobeNewsWire • Nov 17, 2026

Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Biogen Inc. (BIIB) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
CAMBRIDGE, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures of cognition, function and disease progression, with the 60 mg twice-yearly regimen showing the largest treatment effects at two years.
GlobeNewsWire • 19 hours ago

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years TOKYO and CAMBRIDGE, Mass.
PRNewsWire • Nov 16, 2026

TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH. Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatme.
Business Wire • Nov 16, 2026

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration
GlobeNewsWire • Nov 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Biogen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.